









Markets
/
Stocks
/
nasdaq-pen
/

Penumbra Inc

PEN

336.420USD

+0.150+0.04%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

10.04BMarket Cap

73.69P/E TTM



Penumbra Inc

336.420

+0.150+0.04%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Penumbra Inc

Currency: USD Updated: 2026-03-25

Key Insights

Penumbra Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 368.59.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Penumbra Inc's Score

Industry at a Glance

Industry Ranking

67 / 209

Overall Ranking

176 / 4547

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Penumbra Inc Highlights

StrengthsRisks

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.61% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.40B.

Undervalued

The company’s latest PE is 73.65, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 38.56M shares, decreasing 2.94% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 171.00 shares of this stock.

Analyst Rating

Based on 18 analysts

Hold

Current Rating

368.588

Target Price

+9.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Penumbra Inc is 8.57, ranking 25 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 385.38M, representing a year-over-year increase of 22.14%, while its net profit experienced a year-over-year increase of 40.55%.

Score

Industry at a Glance

Previous score

8.57

Change



Financials

9.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.54

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.68

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.42

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Penumbra Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Penumbra Inc is 3.84, ranking 200 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 73.65, which is 2630.94% below the recent high of 2011.41 and 7230.50% above the recent low of -5251.80.

Score

Industry at a Glance

Previous score

3.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/209

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Penumbra Inc is 6.78, ranking 162 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 320.00, with a high of 355.00 and a low of 266.00.

Score

Industry at a Glance

Previous score

6.78

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 18 analysts

Hold

Current Rating

368.588

Target Price

+10.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Penumbra Inc

PEN

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Penumbra Inc is 5.58, ranking 178 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 342.55 and the support level at 331.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.61

Change

0.97

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.424

Sell

RSI(14)

46.583

Neutral

STOCH(KDJ)(9,3,3)

39.580

Neutral

ATR(14)

2.485

Low Volatility

CCI(14)

-21.468

Neutral

Williams %R

61.189

Sell

TRIX(12,20)

-0.069

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

335.654

Buy

MA10

336.425

Sell

MA20

337.871

Sell

MA50

342.953

Sell

MA100

318.283

Buy

MA200

285.313

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Penumbra Inc is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 98.29%, representing a quarter-over-quarter increase of 3.69%. The largest institutional shareholder is The Vanguard, holding a total of 3.76M shares, representing 9.59% of shares outstanding, with 1.23% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.10M

+1.16%

The Vanguard Group, Inc.

Star Investors

3.83M

-0.66%

BlackRock Institutional Trust Company, N.A.

3.58M

-0.69%

T. Rowe Price Associates, Inc.

Star Investors

1.76M

+31.17%

State Street Investment Management (US)

1.16M

-0.49%

Citadel Advisors LLC

971.00K

+343.39%

Baillie Gifford & Co.

Star Investors

908.55K

-1.47%

RTW Investments L.P.

866.50K

+0.34%

Geode Capital Management, L.L.C.

747.77K

+5.86%

Elsesser (Adam)

1.02M

+1.21%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Penumbra Inc is 7.74, ranking 32 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Penumbra Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.